BioPharma Resources

Drug Trial Radar · NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 1,264 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,264

Planned (sponsor's estimate)

Start

Dec 21, 2023

Primary completion

Nov 2027

Study completion Jan 2031

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Neoplasm Metastasis

Interventions

  • LY3537982Drug

    Administered orally.

  • PembrolizumabDrug

    Administered IV.

  • PlaceboDrug

    Administered orally.

  • CisplatinDrug

    Administered IV.

  • CarboplatinDrug

    Administered IV.

  • PemetrexedDrug

    Administered IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)Time frame: Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)
  2. Part A and Part B: Progression-Free Survival (PFS)Time frame: Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)

Locations

415 sites in 29 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama · Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Banner University Medical Center Phoenix

    Phoenix, Arizona · Recruiting

  • The University of Arizona Cancer Center - North Campus

    Tucson, Arizona · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California · Completed

  • BASS Cancer Center

    Walnut Creek, California · Recruiting

  • USO - Rocky Mountain Cancer Centers

    Lone Tree, Colorado · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • Millennium Oncology Research Clinic

    Hollywood, Florida · Recruiting

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida · Recruiting

  • Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala

    Ocala, Florida · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • Comprehensive Hematology Oncology

    St. Petersburg, Florida · Recruiting

  • University Cancer & Blood Center, LLC

    Athens, Georgia · Recruiting

  • Emory University School of Medicine- Grady Campus

    Atlanta, Georgia · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • University of Illinois at Chicago

    Chicago, Illinois · Recruiting

  • University of Chicago Hospital

    Chicago, Illinois · Recruiting

  • Springfield Clinic Main Campus

    Springfield, Illinois · Recruiting

  • Parkview Research Center at Parkview Regional Medical Center

    Fort Wayne, Indiana · Recruiting

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana · Recruiting

  • Franciscan Health

    Indianapolis, Indiana · Recruiting

  • Community Cancer Center North

    Indianapolis, Indiana · Recruiting

  • The University of Kansas Cancer Center - Westwood

    Westwood, Kansas · Recruiting

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky · Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland · Recruiting

  • USO - Maryland Oncology Hematology

    Columbia, Maryland · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • The Cancer & Hematology Centers

    Grand Rapids, Michigan · Recruiting

  • Allina Health Cancer Institute - Abbott Northwestern Hospital

    Minneapolis, Minnesota · Recruiting

  • HealthPartners Cancer Research Center

    Saint Paul, Minnesota · Recruiting

  • North Mississippi Hematology and Oncology Associates

    Tupelo, Mississippi · Recruiting

  • Oncology Hematology Associates

    Springfield, Missouri · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Recruiting

Showing 40 of 415 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.